Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03767244 · ClinicalTrials.gov registry record · Phase 3
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
A Phase 3 study of Prostatic Neoplasms, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 2,517
- Enrollment target
- 20
- Study locations
NCT03767244: Active Phase 3 study of Prostatic Neoplasms, sponsored by Janssen Research & Development.
NCT03767244 is a Phase 3 study of Prostatic Neoplasms that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 2,517 participants, above the 476-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (429% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03767244, a Phase 3 study of Prostatic Neoplasms, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,517 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS) as compared to placebo plus ADT.
Primary Outcome
pCR is assessed by a pathology blinded independent central radiology review (BICR) as defined in the pathology charter.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Apalutamide
- DRUG Androgen Deprivation Therapy (ADT)
Study Locations (20)
California
- UC San Diego Moores Cancer Center - La Jolla
- University of Southern California - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- University of California Los Angeles - Los Angeles
- University of California Irvine Medical Center Chao Family Comprehensive Cancer Center - Orange
- UC Davis Medical Center - Sacramento
Florida
- Urology Specialists LLC - Hialeah
- Mayo Clinic - Division Of Hematology/oncology - Jacksonville
- Miami Cancer Institute at Baptist Health / Baptist Health Medical Group - Miami
- Advent Health - Orlando
Colorado
- AdventHealth Medical Group Urology of Denver - Denver
- Colorado Clinical Research - Lakewood
Massachusetts
- Dana Farber Cancer Institute - Boston
- Beth Isreal Deaconess Medical Center - Boston
Connecticut
- Stamford Hospital - Stamford
Georgia
- Emory University Winship Cancer Institute - Atlanta
Illinois
- University of Chicago - Chicago
Louisiana
- Ochsner LSU Health Shreveport - Regional Urology - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,517 participants |
| Start Date | 2019-06-11 |
| Est. Completion | 2028-10-13 |
| Phase | Phase 3 |
What the registry record for NCT03767244 still lists
NCT03767244 is an interventional study that assigns participants to a tested intervention. Its 2,517 participants enrollment target places it among the larger protocols in the corpus, above the 476-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (429% higher).
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03767244 names 20 study sites across 10 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT03767244 about?
NCT03767244 is a clinical study titled "A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy". The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement ...
What is the current status of trial NCT03767244?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,517 participants. The study started on 2019-06-11. Estimated completion is 2028-10-13.
What conditions does trial NCT03767244 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT03767244?
The interventions under investigation include: Placebo (DRUG), Apalutamide (DRUG), Androgen Deprivation Therapy (ADT) (DRUG).
Who is sponsoring clinical trial NCT03767244?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03767244 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03767244's enrollment target sits among peer trials
2,517 2nd of 65 the highest of 65 other Prostatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RECRUITING · Phase 3
-
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
RECRUITING · Phase 3
-
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RECRUITING · Phase 3
-
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
ACTIVE NOT RECRUITING · Phase 3
-
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI